AISight

AISight, developed by PathAI, is a cloud-native intelligent enterprise workflow solution designed for anatomic pathology laboratories across academic medical centers, reference laboratories, health systems, and biopharma organizations. It serves as a central hub for case management, image management, and artificial intelligence applications, enabling a wide range of histopathology use cases for the world's leading laboratories and research centers.

With over 100 institutions already leveraging the platform, more than 20 AI products accessible for deployment, and over 100 million digital slides managed, AISight provides a comprehensive and scalable foundation for modern digital pathology workflows.

Core Platform Capabilities

• Interoperability: Scanner-agnostic workflow compatible with most major laboratory information systems (LIS) and leading scanners including Hamamatsu, Leica, Roche, and Philips.
• Cloud-Based Architecture: Browser-accessible platform with cloud-based image and data storage, enabling rapid activation and scale without additional infrastructure investment.
• Customizable and Configurable Workflows: Flexible workflow design supports multiple use cases, with advanced user settings and privilege management.
• Open AI Environment: Integrates both PathAI and third-party algorithms to maximize AI deployments across multiple pathologist specialties.
• Pathologist-Centric Design: Built-in image analysis and collaboration tools deliver an intuitive and practical user experience.
• Security and Privacy: ISO 27001 certified and adheres to industry-recognized security and privacy frameworks.

LIS Integration via AISight Link

• AISight Link powers seamless integration between the AISight Image Management System (IMS) and existing laboratory information systems.
• Designed to augment existing digital pathology workflows with minimal disruption and no requirement for additional infrastructure.
• Supports institutions across academic medical centers, reference labs, health systems, and independent pathology labs.

Multi-Partner AI Portfolio

• Offers an integrated ecosystem of AI algorithms developed by top-tier partners including DeepBio, DoMore Dx, Paige, and Visiopharm.
• Each algorithm is fully embedded within the AISight IMS, eliminating complex setups and allowing pathologists to access tools directly within familiar workflows.
• Covers a broad range of tasks including biomarker quantification, primary diagnosis, and prognostication.
• Leverages AISight Link's open API to enable advanced features such as AI Impressions, Fields of Interest, and detailed reporting tools.
• The portfolio continually grows as new AI applications are added, keeping labs at the forefront of digital pathology innovation.

Quality Control Algorithms

• ArtifactDetect and Automated Digital Slide QC: Provides automated, instant detection of non-evaluable slides for re-scanning or re-staining, supporting H&E, IHC, and Trichrome stain types.

Case Prioritization

• TumorDetect for Case Prioritization: Identifies cases with likely tumor presence on H&E slides across all solid tumors, helping reduce turnaround time by expediting IHC orders and second reviews.

Tumor Cellularity Quantification

• AIM-TumorCellularity (AIM-TC): Delivers automated, whole-slide level assessment of tumor cellularity and tumor fraction, providing key results including Total Tissue Area, Total Tumor Area, and Percent Tumor Nuclei.

Disease Severity Assessment

• AIM-MASH and AIM-MASH+: Accurate and precise assessment of MASH disease severity using H&E and Trichrome staining.
• AIM-HI UC: Assessment of Ulcerative Colitis disease severity using Geboes, Nancy, and Robarts scoring on H&E slides.

Biomarker Quantification Algorithms

• AIM-PD-L1: Supports NSCLC (Agilent Dako 28-8 and 22C3; Roche Ventana SP142 and SP263), HNSCC (Dako 28-8), Melanoma (Dako 28-8), and Urothelial (Dako 28-8) indications.
• AIM-HER2: Breast cancer assessment using 4B5 and HercepTest antibodies.
• AIM-ER: Breast cancer estrogen receptor quantification using Dako EP1 and Ventana SP1.
• AIM-PR: Breast cancer progesterone receptor quantification using Dako PgR 636 and Ventana 1E2.
• AIM-Ki-67: Breast cancer proliferation marker quantification using Dako MIB-1 and Ventana 30-9.

Molecular Prediction Algorithms

• Enables biomarker identification directly from H&E whole-slide images (WSI) to accelerate and expand clinical trial enrollment.
• Includes MET Dysregulation prediction for NSCLC indications.

AISight Dx has received FDA clearance for primary diagnosis in the United States with compatible scanners including Hamamatsu NanoZoomer S360MD, Leica Aperio GT 450 DX, Roche VENTANA DP200, and DP600, and holds CE-IVD marking for primary diagnosis in the EEA, UK, and Switzerland. Many PathAI algorithms are currently For Research Use Only in the United States. The platform is actively deployed at leading institutions including Labcorp, University Hospital Zurich, UMC Utrecht, Moffitt Cancer Center, and Northwestern Medicine.